Media formats available:
Recommended
- FDA Drug Information Updates
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
- FDA Drug Information Updates
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
Leonard H. Calabrese, DO
John R. Tesser, MD
- FDA Drug Information Updates
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard